Press release
Liquid Biopsy For Cancer Diagnostics Market Study Explores Industry Growth Toward $22.99 Billion
Liquid Biopsy For Cancer Diagnostics Market
Projected Market Size for Liquid Biopsy for Cancer Diagnostics by 2030
The liquid biopsy for cancer diagnostics market is poised for rapid expansion, expected to reach a valuation of $22.99 billion by 2030. This surge reflects a robust compound annual growth rate (CAGR) of 16.4%. The anticipated growth stems from various factors, including the growing integration of liquid biopsy into routine cancer screening protocols, a rising emphasis on personalized cancer treatments, broader acceptance for monitoring therapy responses, increased investments in diagnostic technologies, and a wider application of liquid biopsy particularly in gastrointestinal and ovarian cancers. Key trends anticipated during this period involve a heightened use of liquid biopsy for lung cancer diagnosis, expanding popularity of blood-based cancer screening methods, escalating demand for real-time monitoring of cancer progression, diversification in cancer types targeted by liquid biopsy, and a stronger clinical preference for minimally invasive diagnostic approaches.
The liquid biopsy for cancer diagnostics market size has grown rapidly in recent years. It will grow from $10.75 billion in 2025 to $12.52 billion in 2026 at a compound annual growth rate (CAGR) of 16.4%. The growth in the historic period can be attributed to limitations of tissue biopsy procedures, increasing incidence of lung and breast cancer, early adoption of molecular cancer diagnostics, growing need for early-stage cancer detection, rising clinical research in oncology diagnostics.
Download a free sample of the liquid biopsy for cancer diagnostics market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12205&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR
Leading Players Driving the Liquid Biopsy for Cancer Diagnostics Market
Several prominent companies have established themselves as frontrunners in the liquid biopsy for cancer diagnostics arena. Industry leaders include F. Hoffman La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., The Menarini Group, Bio-Rad Laboratories Inc., QIAGEN Inc., Exact Sciences Corporation, Bio-Techne Corporation, and ArcherDX Inc. Further notable participants include Neogenomics Laboratories Inc., Guardant Health Inc., Myriad Genetics Inc., Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., Biocartis Group NV, Biodesix Inc., MDx Health Inc., Sysmex Inostics Inc., Biocept Inc., Agena Bioscience Inc., Laboratory for Advanced Medicine (LAM) Inc., MiRXES Pte Ltd., Inivata Limited, Resolution Bioscience Inc., SAGA Diagnostics AB, NuProbe Inc., Personal Genome Diagnostics Inc., Pathway Genomics Corporation, and Angle PLC.
A recent strategic move occurred in February 2024, when Veracyte Inc., a US-based diagnostics firm, acquired C2i Genomics Inc. for around US$70 million. This acquisition is set to strengthen Veracyte's cancer diagnostics portfolio by integrating C2i's AI-powered whole-genome minimal residual disease (MRD) detection technology. The goal is to broaden diagnostic capabilities across the cancer care continuum, enhancing early detection, recurrence tracking, and providing richer insights for both clinicians and patients. C2i Genomics Inc. is known for its expertise in AI-driven whole-genome MRD testing.
View the full liquid biopsy for cancer diagnostics market report:
https://www.thebusinessresearchcompany.com/report/liquid-biopsy-for-cancer-diagnostics-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR
Emerging Technologies and Innovations Shaping the Market
Companies within the liquid biopsy market are focusing heavily on developing cutting-edge solutions, such as advanced liquid biopsy assays. These assays represent highly refined diagnostic tests that analyze liquid biological samples-like blood or other fluids-to identify and characterize cancer-related biomarkers with high precision. For example, in November 2023, Illumina Inc., a global leader in DNA sequencing technology, unveiled the TruSight Oncology 500 ctDNA v2 assay. This research-grade test enables noninvasive comprehensive genomic profiling (CGP) by analyzing circulating tumor DNA (ctDNA) from blood samples. Designed for ease of integration and deeper insight generation, this assay supports cancer research by offering detailed molecular profiles without invasive procedures.
Comprehensive Segmentation of the Liquid Biopsy for Cancer Diagnostics Market
This analysis divides the liquid biopsy market into multiple segments for a clearer understanding:
1) By Type: Products and Services
2) By Sample Source: Blood, Urine, and Saliva
3) By Cancer Type: Lung Cancer, Breast Cancer, Colon Cancer, and Other Cancers
4) By End-User: Hospitals, Diagnostic Centers, and Other End-Users
Further subcategories include:
- Products such as Circulating Tumor Cells (CTCs) Detection Kits, Circulating Tumor DNA (ctDNA) Detection Kits, Exosome Isolation Kits, and Sample Collection Devices.
- Services encompassing Testing Services, Analytical Services, and Bioinformatics Services.
This segmentation provides a detailed framework for understanding the liquid biopsy market's diverse offerings and applications across cancer diagnostics.
New analytical features added to our 2026 market reports:
• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Liquid Biopsy For Cancer Diagnostics Market Study Explores Industry Growth Toward $22.99 Billion here
News-ID: 4609332 • Views: …
More Releases from The Business Research Company
Trypsin-EDTA Solution For Cell Dissociation Market Research Reveals Path To $2.0 …
The trypsin-EDTA solution for cell dissociation market is poised for remarkable expansion as advances in cell therapy and biomanufacturing continue to accelerate. With increasing demands for efficient and reliable cell processing methods, this sector is on track to experience dynamic growth over the next several years. The following overview explores the market's anticipated size, leading companies, emerging trends, and key segmentations shaping its future.
Projected Market Size and Growth Path for…
Triple Negative Breast Cancer Market Demonstrates Long-Term Growth Potential At …
An in-depth look into the triple negative breast cancer market reveals promising growth and significant advancements in treatment options. As research intensifies and new therapies emerge, this sector is poised for notable expansion and increased innovation in the coming years.
Projected Market Growth of the Triple Negative Breast Cancer Market by 2030
The market for triple negative breast cancer is anticipated to experience substantial growth, reaching a valuation of $1.48…
Treatment-Resistant Depression Market Outlook Signals Expansion To $2.59 Billion …
The treatment-resistant depression market is on track for significant expansion as new therapies and technologies emerge to address persistent challenges in managing this complex condition. With ongoing advancements in personalized medicine and digital health, this sector is expected to evolve rapidly in the coming years. Here's an in-depth look at the market size, key players, influential trends, and detailed segmentation shaping the industry's outlook.
Forecast of the Treatment-Resistant Depression Market Size…
Traumatic Brain Injuries Assessment Market Report 2026 Market Outlook Supported …
The assessment of traumatic brain injuries (TBI) is a rapidly evolving field, driven by technological advancements and a growing need for precise and timely diagnosis. As healthcare providers seek more effective tools to evaluate brain trauma, the market for TBI assessment is poised for notable expansion. Below is an in-depth look at how this market is expected to develop, the leading players involved, and the trends shaping its future.
Traumatic Brain…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
